The 1,000L bioreactor is added to the existing manufacturing process trains which include 100L and 500L bioreactors, 100L wave system, 20L and 200L Sartorius subs and a 100L microbial manufacturing train.
Cytovance currently produces antibody, recombinant protein products derived from cell culture at scales up to 500L (w/v) from batch, fed-batch and perfusion processes and microbial production up to 100L scale.
Cytovance president and CEO Darren Head said that the decision to expand the capabilities was made with careful consideration of their clients’ needs.
"The additional state of the art Bioreactor will allow Cytovance to provide clinical material to key clients as they move through the clinic," Head added.